Novocure [NVCR] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Novocure Ltd.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Novocure Ltd. wins in 4 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Novocure Ltd. Abbott Laboratories Better
P/E Ratio (TTM) -10.32 25.97 Abbott Laboratories
Price-to-Book Ratio 4.04 3.09 Abbott Laboratories
Debt-to-Equity Ratio 72.95 26.79 Abbott Laboratories
PEG Ratio 0.16 -1.41 Novocure Ltd.
EV/EBITDA -8.82 13.74 Abbott Laboratories
Profit Margin (TTM) -20.79% 13.90% Abbott Laboratories
Operating Margin (TTM) -21.33% 16.50% Abbott Laboratories
EBITDA Margin (TTM) N/A 16.50% N/A
Return on Equity -38.89% 12.36% Abbott Laboratories
Return on Assets (TTM) -9.06% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-75.68M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 1.31% -34.98% Novocure Ltd.
Price-to-Sales Ratio (TTM) 2.16 3.57 Novocure Ltd.
Enterprise Value $1.19B $166.96B Abbott Laboratories
EV/Revenue Ratio 1.82 3.70 Novocure Ltd.
Gross Profit Margin (TTM) 75.82% N/A N/A
Revenue per Share (TTM) $6 $26 Abbott Laboratories
Earnings per Share (Diluted) $-1.22 $3.57 Abbott Laboratories
Beta (Stock Volatility) 0.82 0.78 Abbott Laboratories
Short % of Float 12.45% 1.53% Abbott Laboratories

Novocure Ltd. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

NVCR
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Novocure Ltd.-1.01%4.45%0.11%42.16%35.70%34.15%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Novocure Ltd.1.31%-59.78%-91.85%63.27%-2.74%-2.74%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Novocure Ltd. vs Abbott Laboratories

MetricNVCRABT
Market Information
Market Cap i$1.46B$160.70B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,138,76213,495,583
90 Day Avg. Volume i1,141,01412,934,461
Last Close$17.60$88.67
52 Week Range$9.82 - $18.92$81.97 - $139.06
% from 52W High-6.98%-36.24%
All-Time High$232.76 (Jun 21, 2021)$142.60 (Dec 27, 2021)
% from All-Time High-92.44%-37.82%
Growth Metrics
Quarterly Revenue Growth0.08%0.08%
Quarterly Earnings Growth0.08%-0.19%
Financial Health
Profit Margin (TTM) i-0.21%0.14%
Operating Margin (TTM) i-0.21%0.17%
Return on Equity (TTM) i-0.39%0.12%
Debt to Equity (MRQ) i72.9526.79
Cash & Liquidity
Book Value per Share (MRQ)$3.03$30.02
Cash per Share (MRQ)$3.93$5.14
Operating Cash Flow (TTM) i$-49,031,000$10.80B
Levered Free Cash Flow (TTM) i$-37,975,376$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Novocure Ltd. vs Abbott Laboratories

MetricNVCR (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-10.3225.97
Forward P/E i-10.4915.29
PEG Ratio i0.16-1.41
Price to Sales (TTM) i2.163.57
Price to Book (MRQ) i4.043.09
Market Capitalization
Market Capitalization i$1.46B$160.70B
Enterprise Value i$1.19B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i1.823.70
Enterprise to EBITDA i-8.8213.74
Risk & Other Metrics
Beta i0.820.78
Book Value per Share (MRQ) i$3.03$30.02

Financial Statements Comparison: Novocure Ltd. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNVCR (2025)ABT (2025)
Revenue/Sales i655.35M44.33B
Cost of Goods Sold i166.88M19.32B
COGS % of Revenue i25.5%43.6%
Gross Profit i488.47M25.01B
Gross Margin i74.5%56.4%
Research & Development i224.54M2.94B
Operating Income (EBIT) i-153.80M8.05B
Operating Margin i-23.5%18.2%
EBITDA i-100.24M12.03B
EBITDA Margin i-15.3%27.1%
Pre-Tax Income i-136.25M8.47B
Pre-Tax Income % of Revenue i-20.8%19.1%
Income Tax i-23,0001.94B
Income Tax % of Revenue i0.0%4.4%
Net Income (Profit) i-136.23M6.52B
Profit Margin i-20.8%14.7%

Balance Sheet & Liquidity Metrics

MetricNVCR (2025)ABT (2025)
Cash & Equivalents i93.55M8.52B
Total Current Assets i646.73M26.00B
Total Current Assets % of Revenue i98.7%58.6%
Total Current Liabilities i223.23M16.50B
Total Current Liabilities % of Revenue i34.1%37.2%
Long-Term Debt i236.69M10.83B
Long-Term Debt % of Revenue i36.1%24.4%
Total Shareholders Equity i340.47M52.77B
Retained Earnings i-1.29B49.78B
Retained Earnings % of Revenue i-196.9%112.3%
Property, Plant & Equipment i115.82M17.57B

Cash Flow Statement Comparison

MetricNVCR (2025)ABT (2025)
Operating Cash Flow i-50.83M10.80B
Operating Cash Flow % of Revenue i-7.8%24.4%
Capital Expenditures i-26.65M-2.17B
Free Cash Flow i-75.68M7.40B
FCF Margin i-11.5%16.7%
Debt Repayment i-560.95M-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricNVCRABT
Shares Short i9.06M23.83M
Short Ratio i6.781.93
Short % of Float i12.45%1.53%
Shares Outstanding i112.49M1.74B
Float Shares i94.63M1.73B
% Held by Insiders i9.32%0.54%
% Held by Institutions i85.24%82.23%
% Held by Public i5.44%17.23%

Dividend Analysis & Yield Comparison: Novocure Ltd. vs Abbott Laboratories

MetricNVCRABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026